Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ +14.29%57 EV-to-EBITDA is 2.03 as of Aug. 28, 2026, which is 30% below its 10-year median of 2.88. GuruFocus rates ASX:EZZ with a GF Score™ of 57/100 and a GF Value™ of A$1.47 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 414 Biotechnology companies, EZZ Life Science Holdings ranks better than 78.02% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EZZ Life Science Holdings's enterprise value is A$12.99 Mil.
EZZ Life Science Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.41 Mil. Therefore, EZZ Life Science Holdings's EV-to-EBITDA for today is 2.03.
The historical rank and industry rank for EZZ Life Science Holdings's EV-to-EBITDA or its related term are showing as below:
ASX:EZZ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.27 Med: 2.88 Max: 18.78
Current: 2.02
During the past 6 years, the highest EV-to-EBITDA of EZZ Life Science Holdings was 18.78. The lowest was -0.27. And the median was 2.88.
ASX:EZZ's EV-to-EBITDA is ranked better than 78.02% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs ASX:EZZ: 2.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EZZ Life Science Holdings (ASX:EZZ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EZZ Life Science Holdings's PE Ratio (TTM) for today is calculated as:
EZZ Life Science Holdings's share price for today is A$0.64.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EZZ vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's EV-to-EBITDA falls into.
EZZ Life Science Holdings's current Enterprise Value is A$12.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EZZ Life Science Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EZZ Life Science Holdings (ASX:EZZ) has a EV-to-EBITDA of 2.03 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EZZ Life Science Holdings. This is 30% below median its historical median of 2.88. According to the industry distribution chart, EZZ Life Science Holdings ranks #91 out of 414 companies in the Biotechnology industry, placing it in the top 22%.
Is EZZ Life Science Holdings' EV-to-EBITDA too high?
EZZ Life Science Holdings' current EV-to-EBITDA of 2.03 is 30% below median its 10-year median of 2.88. The Biotechnology industry median EV-to-EBITDA is 13.55. EZZ Life Science Holdings' value of 2.03 is 85% below this industry median. Based on the distribution chart, EZZ Life Science Holdings ranks #91 out of 414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EZZ Life Science Holdings has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #91 out of 414 companies for EV-to-EBITDA. This places EZZ Life Science Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.55. EZZ Life Science Holdings' value of 2.03 is 85% below this benchmark. While the company's 10-year median is 2.88 vs. the industry median of 13.55, EZZ Life Science Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EZZ Life Science Holdings's current EV-to-EBITDA of 2.03 is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EZZ Life Science Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current EV-to-EBITDA is 2.03, which is 30% below median its own 10-year median of 2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.47, compared to a current price of A$0.64 — trading 56.5% below its estimated fair value. The current EV-to-EBITDA is 2.03, which is 30% below median its 10-year median of 2.88 and 85% below the Biotechnology industry median of 13.55. EZZ Life Science Holdings' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current EV-to-EBITDA is 2.03 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.64 is trading 56.5% below its estimated GF Value™ of A$1.47.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
EV-to-EBITDA: 2.03 (30% below median its 10-year median of 2.88)
GF Value™: A$1.47 vs. price of A$0.64 (56.5% below fair value)
Industry Position: 85% below the Biotechnology median (#91 of 414)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
57GF Score
Get the complete analysis for ASX:EZZ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
